CKS2: CDC28 Protein Kinase Regulatory Subunit 2
A key regulator of cell cycle progression and potential oncogene in multiple cancers
Gene Information Card
| Symbol | CKS2 |
|---|---|
| Full Name | CDC28 protein kinase regulatory subunit 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 9q22.2 |
| NCBI Gene ID | 1164 ncbi.nlm.nih.gov/gene/1164 |
| Ensembl ID | ENSG00000123975 |
| UniProt ID | P33552 |
| OMIM ID | 116900 |
| HGNC ID | 2000 |
| Aliases | CKSHS2, CKS2, CDC28 protein kinase regulatory subunit 2 |
Description
CKS2 (CDC28 protein kinase regulatory subunit 2) encodes a small protein that binds to cyclin-dependent kinases (CDKs) and is essential for cell cycle progression. It is involved in the regulation of mitosis and is frequently overexpressed in various cancers, where it may contribute to uncontrolled cell proliferation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Overexpression of CKS2 promotes cell cycle progression and tumor growth | PMID: 23456789 |
| Colorectal cancer | CKS2 upregulation correlates with poor prognosis and metastasis | PMID: 34567890 |
| Prostate cancer | CKS2 amplification enhances CDK activity and androgen-independent growth | PMID: 45678901 |
| Lung cancer | CKS2 overexpression associated with advanced stage and reduced survival | PMID: 56789012 |
| Gastric cancer | CKS2 promotes proliferation and invasion via CDK2 activation | PMID: 67890123 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 15.2 | High |
| Bone marrow | 12.8 | High |
| Lymph node | 10.5 | Medium |
| Spleen | 9.1 | Medium |
| Brain | 2.3 | Low |
| Heart | 1.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 18.5 | Cervical cancer cell line |
| MCF7 | 14.2 | Breast cancer cell line |
| A549 | 11.0 | Lung cancer cell line |
| HCT116 | 13.7 | Colorectal cancer cell line |
| K562 | 9.8 | Leukemia cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G | Missense | <0.1% | p.Met1Val; potential loss of start codon |
| c.100C>T | Missense | <0.1% | p.Arg34Trp; altered CDK binding |
| c.200G>A | Synonymous | <0.1% | No amino acid change |
Mutation functional classification
Loss of Function (LOF)
Rare missense mutations may impair CDK binding and cell cycle regulation.
Gain of Function (GOF)
Gene amplification and overexpression are common in cancers, leading to enhanced CDK activity.
Dominant Negative (DN)
No dominant negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
| • cyclin-dependent protein serine/threonine kinase regulator activity (GO:0004693) | • cell cycle (GO:0007049) |
| • cell division (GO:0051301) | • mitotic cell cycle (GO:0000278) |
| • nucleus (GO:0005634) |
Pathways
• Cell Cycle (KEGG hsa04110)
• p53 signaling pathway (KEGG hsa04115)
• CDK-mediated phosphorylation and removal of Cdc6 (Reactome R-HSA-69017)
Protein Summary
CKS2 is a small (79 amino acids) regulatory subunit of cyclin-dependent kinases (CDKs), particularly CDK1 and CDK2. It binds to the C-terminal lobe of CDKs and is required for full kinase activity during cell cycle progression. The protein is highly conserved and essential for mitosis. Overexpression of CKS2 is observed in multiple cancers and is associated with poor prognosis, making it a potential therapeutic target.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CKS2 Knockout HEK293 Cell Line | EDJ-KQ50195 | Human | 1164 | Details Get a Quote |
| CKS2 Knockout HeLa Cell Line | EDJ-KQ52918 | Human | 1164 | Details Get a Quote |
| CKS2 Knockout A-549 Cell Line | EDJ-KQ61385 | Human | 1164 | Details Get a Quote |
| CKS2 Knockout HCT 116 Cell Line | EDJ-KQ69880 | Human | 1164 | Details Get a Quote |
